PMID- 37400660
OWN - NLM
STAT- MEDLINE
DCOM- 20230811
LR  - 20230905
IS  - 1433-8726 (Electronic)
IS  - 0724-4983 (Linking)
VI  - 41
IP  - 8
DP  - 2023 Aug
TI  - Urological complications after COVID 19 vaccine according to age, sex and 
      manufacturer.
PG  - 2255-2263
LID - 10.1007/s00345-023-04481-1 [doi]
AB  - OBJECTIVES: To examine the effects of age, sex, and type of COVID-19 vaccine on 
      urological complications after vaccination with COVID-19. MATERIALS AND METHODS: 
      We used the Vaccine Adverse Event Reporting System (VAERS) data from December 
      2020 to August 2022 to analyze urological symptoms post-vaccination adverse 
      events (AEs) associated with COVID-19 vaccines authorized for the U.S. 
      POPULATION: We collected AEs after 1-2 dose vaccination in VAERS, but not those 
      after an additional booster shot. Age was divided into three groups (< 18 years, 
      18-64 years, and > 64 years), and compared incidence of AEs after vaccination 
      with either mRNA vaccine (mRNA-1273, Moderna; and BNT162b2, Pfizer-BioNTech) or a 
      viral vector vaccine (JNJ-78436735, Janssen/Johnson and Johnson) as reported in 
      VAERS data. RESULTS: Cumulative incidence rates (CIRs) of LUTS, voiding symptom, 
      storage symptom, infection, and hematuria were 0.057, 0.282, 0.223, 1.245, and 
      0.214, respectively. By gender, CIRs OF LUTS, storage symptom, and infection were 
      statistically significantly higher in women, whereas CIRs of voiding symptom and 
      hematuria were statistically significantly higher in men. CIRs of AEs per 100,000 
      in age groups of < 18 years, 18-64 years, and > 64 years were 0.353, 1.403, and 
      4.067, respectively. All AE types except for voiding symptom displayed the 
      highest CIRs in the Moderna vaccine group. CONCLUSIONS: Based on an updated 
      analysis of available data, the prevalence of urologic complications following 
      administration of COVID-19 vaccines is low. However, specific urologic 
      complications such as gross hematuria are not low in incidence.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Shim, Sung Ryul
AU  - Shim SR
AD  - Department of Biomedical Informatics, College of Medicine, Konyang University, 
      158 Gwanjeodong-ro, Seo-gu, Daejeon, 35365, Republic of Korea.
AD  - Evidence Based Research Center, Kyungnam University, Changwon, Republic of Korea.
FAU - Kim, Kwang Taek
AU  - Kim KT
AD  - Department of Urology, Gil Medical Center, Gachon University College of Medicine, 
      Incheon, Republic of Korea.
FAU - Park, Eunju
AU  - Park E
AD  - Evidence Based Research Center, Kyungnam University, Changwon, Republic of Korea.
AD  - Department of Food and Nutrition, Kyungnam University College of Health Sciences, 
      Changwon, Republic of Korea.
FAU - Pyun, Jong Hyun
AU  - Pyun JH
AD  - Department of Urology, Kangbuk Samsung Hospital, Kangbuk Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul, 
      03181, Korea. docpjh79@hanmail.net.
FAU - Kim, Jae Heon
AU  - Kim JH
AUID- ORCID: 0000-0002-4490-3610
AD  - Department of Urology, Soonchunhyang University Hospital, Soonchunhyang 
      University College of Medicine, 59 Daesagwan-ro, Yongsan-gu, Seoul, 04401, 
      Republic of Korea. piacekjh@hanmail.net.
FAU - Chung, Benjamin I
AU  - Chung BI
AD  - Department of Urology, Stanford University Medical Center, Stanford, CA, USA.
LA  - eng
PT  - Journal Article
DEP - 20230703
PL  - Germany
TA  - World J Urol
JT  - World journal of urology
JID - 8307716
RN  - 0 (COVID-19 Vaccines)
RN  - JT2NS6183B (Ad26COVS1)
RN  - 0 (BNT162 Vaccine)
SB  - IM
MH  - Male
MH  - Female
MH  - Humans
MH  - Adolescent
MH  - *COVID-19 Vaccines/adverse effects
MH  - Ad26COVS1
MH  - BNT162 Vaccine
MH  - Hematuria/epidemiology/etiology
MH  - *COVID-19/epidemiology/prevention & control
OTO - NOTNLM
OT  - COVID-19
OT  - Urologic side effects
OT  - Urologic symptoms
OT  - Vaccination
EDAT- 2023/07/04 01:05
MHDA- 2023/08/11 06:42
CRDT- 2023/07/03 23:28
PHST- 2023/02/13 00:00 [received]
PHST- 2023/06/05 00:00 [accepted]
PHST- 2023/08/11 06:42 [medline]
PHST- 2023/07/04 01:05 [pubmed]
PHST- 2023/07/03 23:28 [entrez]
AID - 10.1007/s00345-023-04481-1 [pii]
AID - 10.1007/s00345-023-04481-1 [doi]
PST - ppublish
SO  - World J Urol. 2023 Aug;41(8):2255-2263. doi: 10.1007/s00345-023-04481-1. Epub 
      2023 Jul 3.